388 related articles for article (PubMed ID: 31362654)
1. Recent Progress in Gene Therapy and Other Targeted Therapeutic Approaches for Beta Thalassemia.
Hamed EM; Meabed MH; Aly UF; Hussein RRS
Curr Drug Targets; 2019; 20(16):1603-1623. PubMed ID: 31362654
[TBL] [Abstract][Full Text] [Related]
2. New therapeutic targets in transfusion-dependent and -independent thalassemia.
Cappellini MD; Motta I
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):278-283. PubMed ID: 29222267
[TBL] [Abstract][Full Text] [Related]
3. Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease.
Khosravi MA; Abbasalipour M; Concordet JP; Berg JV; Zeinali S; Arashkia A; Azadmanesh K; Buch T; Karimipoor M
Eur J Pharmacol; 2019 Jul; 854():398-405. PubMed ID: 31039344
[TBL] [Abstract][Full Text] [Related]
4. Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation.
Motta I; Bou-Fakhredin R; Taher AT; Cappellini MD
Drugs; 2020 Jul; 80(11):1053-1063. PubMed ID: 32557398
[TBL] [Abstract][Full Text] [Related]
5. Beta Thalassemia: Monitoring and New Treatment Approaches.
Khandros E; Kwiatkowski JL
Hematol Oncol Clin North Am; 2019 Jun; 33(3):339-353. PubMed ID: 31030806
[TBL] [Abstract][Full Text] [Related]
6. Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia.
Thompson AA; Walters MC; Kwiatkowski J; Rasko JEJ; Ribeil JA; Hongeng S; Magrin E; Schiller GJ; Payen E; Semeraro M; Moshous D; Lefrere F; Puy H; Bourget P; Magnani A; Caccavelli L; Diana JS; Suarez F; Monpoux F; Brousse V; Poirot C; Brouzes C; Meritet JF; Pondarré C; Beuzard Y; Chrétien S; Lefebvre T; Teachey DT; Anurathapan U; Ho PJ; von Kalle C; Kletzel M; Vichinsky E; Soni S; Veres G; Negre O; Ross RW; Davidson D; Petrusich A; Sandler L; Asmal M; Hermine O; De Montalembert M; Hacein-Bey-Abina S; Blanche S; Leboulch P; Cavazzana M
N Engl J Med; 2018 Apr; 378(16):1479-1493. PubMed ID: 29669226
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological and molecular approaches for the treatment of β-hemoglobin disorders.
Lohani N; Bhargava N; Munshi A; Ramalingam S
J Cell Physiol; 2018 Jun; 233(6):4563-4577. PubMed ID: 29159826
[TBL] [Abstract][Full Text] [Related]
8. β-Thalassemia: evolving treatment options beyond transfusion and iron chelation.
Langer AL; Esrick EB
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):600-606. PubMed ID: 34889443
[TBL] [Abstract][Full Text] [Related]
9. Preclinical transfusion-dependent humanized mouse model of beta thalassemia major.
Huo Y; McConnell SC; Ryan TM
Blood; 2009 May; 113(19):4763-70. PubMed ID: 19258591
[TBL] [Abstract][Full Text] [Related]
10. Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice.
Sii-Felice K; Giorgi M; Leboulch P; Payen E
Exp Hematol; 2018 Aug; 64():12-32. PubMed ID: 29807062
[TBL] [Abstract][Full Text] [Related]
11. Defining curative endpoints for transfusion-dependent β-thalassemia in the era of gene therapy and gene editing.
Corbacioglu S; Frangoul H; Locatelli F; Hobbs W; Walters M
Am J Hematol; 2024 Mar; 99(3):422-429. PubMed ID: 38100154
[TBL] [Abstract][Full Text] [Related]
12. β-Thalassemia gene editing therapy: Advancements and difficulties.
Hu J; Zhong Y; Xu P; Xin L; Zhu X; Jiang X; Gao W; Yang B; Chen Y
Medicine (Baltimore); 2024 May; 103(18):e38036. PubMed ID: 38701251
[TBL] [Abstract][Full Text] [Related]
13. β-Thalassemia intermedia: a comprehensive overview and novel approaches.
Asadov C; Alimirzoeva Z; Mammadova T; Aliyeva G; Gafarova S; Mammadov J
Int J Hematol; 2018 Jul; 108(1):5-21. PubMed ID: 29380178
[TBL] [Abstract][Full Text] [Related]
14. Gene Therapy and Genome Editing.
Boulad F; Mansilla-Soto J; Cabriolu A; Rivière I; Sadelain M
Hematol Oncol Clin North Am; 2018 Apr; 32(2):329-342. PubMed ID: 29458735
[TBL] [Abstract][Full Text] [Related]
15. Betibeglogene Autotemcel Gene Therapy for Non-β
Locatelli F; Thompson AA; Kwiatkowski JL; Porter JB; Thrasher AJ; Hongeng S; Sauer MG; Thuret I; Lal A; Algeri M; Schneiderman J; Olson TS; Carpenter B; Amrolia PJ; Anurathapan U; Schambach A; Chabannon C; Schmidt M; Labik I; Elliot H; Guo R; Asmal M; Colvin RA; Walters MC
N Engl J Med; 2022 Feb; 386(5):415-427. PubMed ID: 34891223
[TBL] [Abstract][Full Text] [Related]
16. New strategies in the treatment of the thalassemias.
Schrier SL; Angelucci E
Annu Rev Med; 2005; 56():157-71. PubMed ID: 15660507
[TBL] [Abstract][Full Text] [Related]
17. Beta-thalassemia.
Galanello R; Origa R
Orphanet J Rare Dis; 2010 May; 5():11. PubMed ID: 20492708
[TBL] [Abstract][Full Text] [Related]
18. Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules.
Chaidos A; Makis A; Hatzimichael E; Tsiara S; Gouva M; Tzouvara E; Bourantas KL
Acta Haematol; 2004; 111(4):189-95. PubMed ID: 15153710
[TBL] [Abstract][Full Text] [Related]
19. CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia.
Zeng S; Lei S; Qu C; Wang Y; Teng S; Huang P
Hum Genet; 2023 Dec; 142(12):1677-1703. PubMed ID: 37878144
[TBL] [Abstract][Full Text] [Related]
20. Infusion of autologous retrodifferentiated stem cells into patients with beta-thalassemia.
Abuljadayel IS; Quereshi H; Ahsan T; Rizvi S; Ahmed T; Khan SM; Akhtar J; Dhoot G
ScientificWorldJournal; 2006 Oct; 6():1278-97. PubMed ID: 17041717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]